New challenges in the treatment of early breast cancer or surgery for early breast cancer... Can less be more ?

Acta Chirurgica Belgica

Volumn 102, Issue 2, 2002, Pages 97-109

  Meurisse, M ^a   Defechereux, Th ^a   Meurisse, N ^a   Bataille, Y ^a   Hamoir, E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Breast conserving therapy; Chemotherapy; Diagnosis; Early Breast cancer; Genetic predisposition; High risk patient; Hormonotherapy; Screening; Sentinel lymph node

Indexed keywords

BREAST TUMOR; FEMALE; HUMAN; REVIEW; TIME;

BREAST NEOPLASMS; FEMALE; HUMANS; TIME FACTORS;

EID: 0036545540     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2002.11679274     Document Type: Article

References (69)

1. BONADONNA G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52 : 2127-2137.
2. KARRISON T G., FERGUSON D. J., MEIER P. Dormancy of mammary carcinoma after mastectomy J Natl Cancer Inst, 1999, 91 : 80-85.
3. FISHER B The evolution of paradigms for the management of breast cancer : a personal perspective. Cancer Res, 1992, 52 (12) : 3512.
4. SCHMIDT J. E. Natural history of breast cancer (letter). Lancet, 1992, 339 : 810.
5. KERLIKOWSKE K., GRADY D., RUBIN S. M. Efficacy of screening mammography : A meta-analysis JAMA, 1995, 273 : 149-154
6. HENDRICK R. E., SMITH R. A., RUTLEDGE J. H. Benefit of screening mammography in women age 40-49 : A new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst, 1997, 22 : 87-92.
7. BAINES C. J., MILLER A. B. Mammography versus clinical examination of the breasts. Monogr Natl Cancer Inst, 1997, 22 : 125-129.
8. MILLER A. B , BAINES C. J., To T. Canadian National Breast Screening Study : 1. Breast cancer detection and death rates among women aged 40-49 years. Can Med Assoc J, 1992, 147 : 1459-1476.
9. MILLER A. B., BAINES C. J., To T. Canadian National Breast Screening Study : 1 Breast cancer detection and death rates among women aged 50-59 years. Can Med Assoc J. 1992, 147 . 1477-1488.
10. VAN NETTEN J. P., RUSS A. S., CANN S. A. Is breast cancer a progressive or systemic disease (letter). Lancet, 1995, 345 : 319-320
11. GAMEL J. W , EDWARDS M. J. Parametric models of therapeutic efficacy in breast cancer (letter). N Engl J Med, 1996. 344 : 1270-1271
12. TABAR L., FAGERBERG G., DAY N. E. What is the optimum interval between mammographic screening examinations ? An analysis based on the latest results of the Swedish Two-County Breast cancer screening trial. Br J Cancer, 1987, 55 : 547-551.
13. MANDELBLATT J. S., WHEAT M. E., MONANE M. Breast cancer screening for elderly women with and without cornorbid conditions : A decision analysis model. Ann Intern Med, 1992, 116 : 722-730.
14. FAULK R. M., SICKLES E. A., SOLLITTO R. A. Clinical efficacy of mammographic screening in the elderly. Radiology, 1995, 194: 193-197.
15. YANCIK R., RIES L. G., YATES J. W. Breast cancer in aging women : A population-based study of contrasts in stage, surgery, and survival. Cancer, 1989, 63 : 976-981.
16. WELCH H. G., ALBERTSEN P. C., NEASE R. F. Estimating treatment benefits for the elderly : The effect of competing risks. Ann Intern Med, 1996. 124 : 577-584.
17. TABAR L., FOGERBERG G., DAY N E Efficacy of breast cancer screening by age : New results from the Swedish Two-County trial. Cancer, 1995, 75 : 2507-2517.
18. Kerlikowske K., Grady D., Barclay J. Effect of age, breast density and family history on the sensitivity of first screening mammography JAMA, 1996, 276 : 33-38.
19. SHAPIRO S , VENET W., STRAX P. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst, 1982, 69 . 349-355.
20. DREW P J., TURNBULL L. W., CHATTERJEE S., READ J. Prospective comparison of standard triple assessment and dynamic magnetic resonance imaging of the breast for the evaluation of symptomatic breast lesions. Ann Surg, 1999, 230 : 680-685.
21. KINKEL K.. HELBICH T. H., ESSERMAN L J., BARCLAY J. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions : diagnostic criteria and intcrobserver variability. AJR Am J Roentgenol, 2000, 175 : 35-43.
22. VAN ONGEVAL C. MR imaging of the breast - present indications. JBR-BTR, 2000, 83 : 80-84.
23. ENRICHI A. Magnetic resonance spectroscopy. Cancer Forum, 2000, 24 : 210-212.
24. KVISTAD K A., BAKKEN I. J., GRIBBESTAD I S., EHRNHOLM B. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging, 1999, 10: 159-164.
25. KHALKHALI I., VILLANUEVA-MEYER J., EDELL S. L , CONNOLLY J. L. Diagnostic accuracy of 99mTc-sestarmbi breast imaging : multicenter trial results. J Nucl Med, 2000, 41 1973-1979.
26. WONG A. Y., SALISBURY E., BILOUS M. Recent developments in stereotactic breast biopsy methodologies . an update for the surgical pathologist. Adv Anat Pathol, 2000, 7 (1) : 26-35.
27. PISANO F., D., YAFFE M. J., HEMMINGER B. M., HENDRICK R. E., NIKLASON L. T., MAIDMENT A. D. Current status of full-field digital mammography. Acad Radiol, 2000, 7 (4) : 266-280.
28. FISHER B , ANDERSON S., REDMOND C. K Reanalysis and resukts after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med, 1995, 333 : 1456-1461.
29. VERONESI U., SALVADORI B., LUINI A. Breast conservation is a safe method in patients with small cancers of the breast. Long-term results of threee randomized trials on, 1973 patients. Eur J Cancer, 1995, 31A : 1574-1579.
30. ABNER A., GELMAN R., CONNOLLY J. The relationship between microscopic margins of resection and the risk of Ilocal recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer, 1994, 74 : 1746-1751.
31. KROLL S. S., SCHUSTERMAN M. A., TADJALLI H E Risk of recurrence after treatment of early breast cancer with skin-sparing mastectomy. Ann Surg Oncol, 1998, 4 : 193-197.
32. FISHER B. Preoperative chemotherapy : a model for studying the biology and therapy of primary breast cancer. J Clin Oncol, 1995, 13 : 537-540.
33. FISHER B. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer : Findings from National Surgical Adjuvant Breast and Bowel project B-18. J Clin Oncol, 1997, 15 : 2483-2493.
34. FISHER B., ANDERSON S., FISHER E. R. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancer, 1991, 338 (8763): 327-331.
35. ROSE M. A., HENDERSON I. C., GELMAN R. et al. Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure. Int J Radiat Oncol Biol Phys, 1989, 17 : 711-717.
36. LACOUR J., BUCALOSSI R, CACERS E. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Cancer, 1976, 37 : 206-214.
37. LIN P. P., ALLISON D. C., WALNSTOCK J. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol, 1993, 11 (8) . 1536-1544.
38. GIULIANO A. E., KIRGAN D. M., GUENTHER J. M Lymphatic mapping and sentinel lymphadenomectomy for breast cancer. Ann Surg, 1994, 220 (3) : 391-401.
39. CABANAS R. M. An approach for the treatment of penile carcinoma. Cancer, 1977, 39 : 456-466
40. MORTON D. L., WEN D. R , WONG J. H. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg, 1992, 127 : 392-399.
41. KRAG D., WEAVER D., ASHIKAGA T. The sentinel node in breast cancer. N Engl J Med, 1998, 339 : 941-946.
42. GIULIANO A. E., DALE P. S , TURNER R. R. Improved axillary staging of breast cancer with sentinel lymph node lymphadenectomy. Ann Surg, 1995, 222 : 394-399
43. QUIET C. A., FERGUSON D J., WEICHSELBAUM R. R. Natural history of node-negative breast cancer : A study of 826 patients with long-term follow-up. J Clin Oncol, 1995, 13 : 1144-1151.
44. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer : an overview of the randomised trials. Lancet, 1998, 351 (9114) : 1451-1467.
45. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer : an overview of the randomised trials. Lancet, 1998, 352 (9132) : 930-942.
46. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer : an overview of 61 randomized trials among 28 896 women. N Engl J Med, 1988, 319(26): 1681-1692.
47. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy . 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet, 1992, 339 (8785):71-85.
48. GOLDHIRSH A , GLICK J H., GELBER R. D. Meeting highlights : International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst, 1998, 90 : 1601-1608.
49. WOOD W. C., BUDMAN D. R., KORZUN A. H. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomas. N Engl J Med, 1994, 330 : 1253-1259.
50. THOR A. D., BERRY U. A., BUDMAN D. R. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst, 1998, 90: 1346-1360.
51. HRYNIUK W., LEVINE M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol, 1986, 4 : 1162-1170.
52. GUSTERSON B. A., GELBER R. D., GOLDHIRSH A. Prognostic importance of cerbB-2 expression in breast cancer. J Clin Oncol. 1992, 10: 1049-1056.
53. SLAMON D., LEYLAND-JONES B., SHAK S. Addition of herceptin (Humanized anti HER 2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increase anticancer activity . a randomized, multinational controlled phase III trial. Proceedings of the American Society of Clinical Oncology, 1998, 17: 377A
54. OFFIT K., BROWN K. Quantitative familial cancer risk : a resource for clinical oncologists. J Clin Oncol, 1994, 12 : 1724-1730.
55. CLAUS E. B., RISCH N. J., THOMPSON W D. Genetic analysis of breast cancer in the cancer and steroids hormone study. Am J Hum Genet, 1991, 48 : 232-237.
56. Easton D. B., Bishop D. T., Ford D. Genetic linkage analysis in familial breast and ovarian cancer : Results from 214 families. Am J Hum Genet, 1993, 52 : 678-683.
57. HALL J. M., LEE M. K., NEWMAN B. Linkage of early onset familial breast cancer to chromosome 17q21. Nature, 1990, 250 : 1684-1688.
58. WOOSTER R., NEUHAUSEN S., MANGION J. Localization of breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994, 265 : 2088-2091.
59. FORD D., EASTON D. B., STRATION M Breast cancer linkage consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet, 1998, 62 : 676-681.
60. ZHANG H., TOMBLINE G., WEGER B BRCA1, BRCA2 and response : Collision or collusion. Cell, 1998, 92 : 433-437.
61. EASTON D. B. Breats caner genes : what are the real risks ? Nat Genet, 1997, 16 : 210-217.
62. ROBSON M., GILEWSKI T., HAAS B. BRCA-associated breast cancer in young women. J Clin Oncol, 1998, 16 : 1642-1648.
63. LERMAN C.. SCHWARTZ M. Adherence and psychological adjustement among women at high risk for breast cancer. Breats Cancer Res Treat, 1993, 28 : 145-155.
64. HARMS S. E. Breast magnetic resonance imaging. Semin Ultrasound CT MR, 1998, 19: 104-120.
65. HARTMANN L. C , SCHAID D. J., WOODS J. E. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med, 1999, 340 , 77-84.
66. REBBECK T., LEVIN A., DALY M. Cancer risk reduction by prophylactic surgery in BRCA1 and BRCA2 mutation carriers (Abstract). Am J Hum Genet, 1998, 63 : A47.
67. OSBORNE M. P. Hormonal intervention in breast cancer : Past, present and future. N Y Acad Sci, 1996, 784 : 427-432.
68. FISHER B., CONSTANTINO J. P., WICKERHAM D. L. Tamoxifen for prevention of breast cancer : Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 1998, 90: 1371-1388.
69. JORDAN V. C., GLUSMAN J. E., ECKERT S. Incident primary breast cancers are reduced by raloxifene . integrated data from multicenter, double blind, randomized trials in 12000 postmenopausal women (Abstract). Proceedings of the American Society of Clinical Oncology, 1998, 17 : 122A.